Related Experiment Video

Updated: Jun 25, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Hepatitis B and hepatitis C in 2009

Patrick Marcellin1

  • 1Service d'Hépatologie, AP-HP and INSERM U773, Centre de Recherche Biologique Bichat-Beaujon CRB3, Université Denis Diderot-Paris 7, Hôpital Beaujon, Clichy, France. patrick.marcellin@bjn.aphp.fr

Liver International : Official Journal of the International Association for the Study of the Liver
|February 12, 2009
PubMed

Insights

Hepatitis B (HBV) and Hepatitis C (HCV) infections cause significant global health issues, leading to cirrhosis, liver cancer, and transplantation. Advances in understanding and treatment offer hope for improved patient outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are prevalent viral infections globally.
  • Chronic HBV and HCV infections are leading causes of liver cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation.
  • These conditions result in substantial morbidity and mortality worldwide.

Purpose of the Study:

  • To review the current understanding of HBV and HCV infection epidemiology and natural history.
  • To highlight recent advancements in therapeutic strategies for HBV and HCV.
  • To discuss the potential impact of emerging treatments on patient outcomes.

Main Methods:

  • Literature review of epidemiological data on HBV and HCV.
  • Analysis of clinical studies on the natural history of chronic hepatitis B and C.
  • Evaluation of recent therapeutic advancements and ongoing clinical trials for HBV and HCV treatments.

Main Results:

  • Significant progress has been made in understanding the epidemiology and natural history of HBV and HCV infections.
  • Therapeutic efficacy for hepatitis B and C has considerably improved with new drug development.
  • Ongoing research and new strategies show promise for further enhancing treatment effectiveness.

Conclusions:

  • HBV and HCV infections remain critical global health challenges.
  • Improved knowledge and evolving therapies are enhancing the management of chronic hepatitis B and C.
  • Future therapeutic developments are expected to further improve outcomes for patients with HBV and HCV-related liver disease.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...